Slow Capital’s Foghorn Therapeutics FHTX Stock Holding History

Slow Capital’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-655	Closed	-$4.06K	–	144
2023 Q1	$4.06K	Buy	+655	New	+$4.29K	﹤0.01%	165

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Slow Capital's FHTX Position: Q2 2023 in Review

Slow Capital sold out of Foghorn Therapeutics (FHTX) in Q2 2023, closing a stake of 655 shares — an estimated $4.06K sold.

Slow Capital first reported a position in FHTX in Q1 2023 and held it in 1 quarter. The position peaked at $4.06K in Q1 2023. 59 funds tracked by Wall St. Rank hold FHTX as of Q2 2023.

Slow Capital reported no remaining Foghorn Therapeutics position as of Q2 2023 after selling out during the quarter.
Slow Capital sold 655 Foghorn Therapeutics shares in Q2 2023, an estimated $4.06K.
Slow Capital first reported a position in Foghorn Therapeutics in Q1 2023 and held it in 1 quarter.
Slow Capital's Foghorn Therapeutics position peaked at $4.06K in Q1 2023.
59 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2023.

Based on Slow Capital's 13F filing for Q2 2023, filed 9 Aug 2023.